tirzepatide and semaglutide versus for Obesity Management: What the SURMOUNT-5 Trial Tells Us Switching From Tirzepatide to Semaglutide:

This decrease in glutathione, alongside the down-regulation of GCLC, indicates a potential correlation between glutathione metabolism and Parkinson's disease, highlighting GCLC and glutathione as promising diagnostic markers for PD

Retatrutide is an unlicensed triple incretin receptor agonist (GLP-1, GIP, glucagon) still in clinical trials

11 Biohaven (Taldefgrobep alfa): An engineered myostatin trap fusion protein

Taking slow sips, and chatting with friends to distract you, can help reduce your blood alcohol level

DOI: 10.1186/s12967-024-05753-z [Google Scholar] Kantreva K, Katsaounou P, Saltiki K, Trakada G, Ntali G, Stratigou T, et al

Afshin A, Forouzanfar MH, Reitsma MB, et al